Mead Johnson Misses Q2 Earnings by a Penny; Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 11:35AM CDT
Mead Johnson (MJN) posted dismal financial numbers in the second quarter of 2015, missing the Zacks Consensus Estimate on both lines
MJN: 75.10 (+0.59), RMTI: 13.46 (+2.37), NUVA: 49.60 (-0.06)
Medtronic Launches GenCut Lung Cancer Biopsy System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 16, 1:20PM CDT
Medtronic's (MDT) GenCut system enables pulmonologists and thoracic surgeons to collect multiple core samples from lesions deep inside the lungs.
MDT: 74.11 (+0.68), RMTI: 13.46 (+2.37), NUVA: 49.60 (-0.06)
Will Mead Johnson's Weak Q2 Preliminary Sales Hurt Growth? (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 3:34PM CDT
Mead Johnson Nutrition Company (MJN) recently released its preliminary results for the second quarter of 2015, which was followed by a revised guidance pertaining to the company's full-year 2015 financial performance.
MJN: 75.10 (+0.59), RMTI: 13.46 (+2.37), NUVA: 49.60 (-0.06)
Will Mead Johnson's Weak Q2 Preliminary Sales Hurt Growth? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 1:20PM CDT
Per the preliminary results, Mead Johnson's (MJN) second-quarter 2015 sales performance appears quite bleak.
MJN: 75.10 (+0.59), RMTI: 13.46 (+2.37), NUVA: 49.60 (-0.06)
Complexities Of Eye Care Drive Strong Moats
Morningstar - at Seeking Alpha - Fri Mar 06, 4:10PM CST
By David Krempa, CFA We see attractive growth opportunities for the ophthalmology market. We see strong competitive advantages in the $50 billion ophthalmology market as a result of manufacturing complexity, strict government regulation, limited...
AGN: 278.13 (+4.05), ABT: 42.22 (+0.35), JNJ: 98.24 (+1.09), VRX: 177.56 (+8.69), AKRX: 29.35 (+0.25), LUX: 71.60 (-0.23), COO: 144.34 (-0.89), REGN: 514.59 (-4.76), NVS: 95.03 (+1.17)